An Evaluation of the Spectra Optia CMNC Collection Procedure

NACompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Healthy Apheresis DonorsMononuclear (MNC) Cell Donors
Interventions
DEVICE

Spectra Optia CMNC

The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.

DEVICE

COBE Spectra MNC

It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.

DRUG

Granulocyte-colony stimulating factor (G-CSF)

Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.

Trial Locations (2)

38104

Key Biologics, LLC, Memphis

45267-0055

Hoxworth Blood Center, Cincinnati

All Listed Sponsors
lead

Terumo BCT

INDUSTRY

NCT02253160 - An Evaluation of the Spectra Optia CMNC Collection Procedure | Biotech Hunter | Biotech Hunter